Close Menu

MOUNTAIN VIEW, California (GenomeWeb) – Free from political pressures, Robert Califf, who on Jan. 20 stepped down as US Food and Drug Administration commissioner, candidly spoke at a conference yesterday about the need for greater oversight of laboratory-developed tests.

While a swathe of the lab industry would disagree, investors and drugmakers at the Personalized Medicine World Conference (PMWC) conceded that regulation isn't always a negative, and has, for example, spurred greater use of biomarkers in drug development to improve understanding of disease biology.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov
14
Sponsored by
Qiagen

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.